Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
4 studies found for:    16236738 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Active, not recruiting Doxorubicin and Cyclophosphamide Plus Paclitaxel With or Without Trastuzumab in Treating Women With Node-Positive Breast Cancer That Overexpresses HER2
Condition: Breast Cancer
Interventions: Biological: herceptin;   Drug: adriamycin;   Drug: cyclophosphamide;   Drug: taxol
2 Completed A Phase II Study of Neoadjuvant Trastuzumab+Docetaxel+NPLD+/-Bevacizumab in Her2-pos. Early Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Trastuzumab, Docetaxel;   Drug: Trastuzumab, Docetaxel, Bevacizumab;   Drug: Trastuzumab+Docetaxel+NPLD;   Drug: Trastuzumab+Docetaxel+NPLD+Bevacizumab
3 Recruiting Safety and QoL of Trastuzumab With Lapatinib or Chemiotherapy in MBC and HER2+ Patients Refractory to Anti HER2 Therapies
Condition: Metastatic Breast Cancer
Interventions: Drug: Lapatinib;   Drug: Trastuzumab
4 Active, not recruiting Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer
Conditions: Breast Adenocarcinoma;   HER2 Positive Breast Carcinoma;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer
Interventions: Drug: Doxorubicin Hydrochloride;   Drug: Cyclophosphamide;   Drug: Paclitaxel;   Biological: Trastuzumab;   Drug: Tamoxifen Citrate;   Drug: Aromatase Inhibition Therapy;   Other: Laboratory Biomarker Analysis

Indicates status has not been verified in more than two years